Management of patients with hepatitis B in special populations

Table 1 Studies of nucleos/tide analogs in patients with hepatitis B related decompensated cirrhosis (adapted by Cholongitas et al[88])

Ref.	Number of patients	NA(s) used	1-yr data		Prognostic factors for the outcome
			↓ CTP score≥2, (%)	MELD score ↑
Fontana et al[17]	154	LAM	NR	NR	Serum bilirubin and creatinine levels at baseline
Schiff et al[18]	226	ADV	NR	-2	NR
Shim et al[19]	70	ETV	49	-2.2	NR
Liaw et al[20]	45/45/22	TDF/TDF + FTC/ETV	26/48/42	-2/-2/-2	NR
Chan et al[21]	114/114	LdT/LAM	32/39	-1.0/-2.0	NR
Hyun et al[22]	45/41	ETV/LAM	NR/NR	-4.9/-3.7	Baseline CTP and MELD at 3 mo
Cholongitas et al[23]	52	ETV/TDF	23.8/19.3	-0.4/-2.2	Changes in MELD score between baseline and 6 mo

NA: Nucleos/tide analogs; ADV: Adefovir; CTP: Child-Turcotte-Pugh; ETV: Entecavir; TDF: Tenofovir; FTC: Emtricitabine; HBV: Hepatitis B virus; LAM: Lamivudine; LdT: Telbivudine; MELD: Model for end stage liver disease; NR: Not reported.